| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Wilson MJ, Dekker J, Harlaar JJ, et al. The role of preoperative iron deficiency in colorectal cancer patients: prevalence and treatment[J]. Int J Colorectal Dis, 2017, 32(11): 1617-1624.
|
| [3] |
Yang L, Xiong Z, Xie Q, et al. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer[J]. BMC Cancer, 2018, 18(1): 558.
|
| [4] |
Trosko JE, Lenz HJ. What roles do colon stem cells and gap junctions play in the left and right location of origin of colorectal cancers?[J]. J Cell Commun Signal, 2017, 11(1): 79-87.
|
| [5] |
Marzouk O, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer[J]. Cancers (Basel), 2011, 3(2): 2767-2810.
|
| [6] |
Segev L, Kalady MF, Church JM. Left-sided dominance of early-onset colorectal cancers: A rationale for screening flexible sigmoidoscopy in the young[J]. Dis Colon Rectum, 2018, 61(8): 897-902.
|
| [7] |
Mik M, Berut M, Dziki L, et al. Right- and left-sided colon cancer - clinical and pathological differences of the disease entity in one organ[J]. Arch Med Sci, 2017, 13(1): 157-162.
|
| [8] |
Bordaçahar B, Barret M, Terris B, et al. Sessile serrated adenoma: from identification to resection[J]. Dig Liver Dis, 2015, 47(2): 95-102.
|
| [9] |
Benedix F, Kuester D, Meyer F, et al. Influence of mucinous and signet-ring cell differentiation on epidemiological,histological, molecular biological features, and outcome in patients with colorectal carcinoma[J]. Zentralbl Chir, 2013, 138(4): 427-433.
|
| [10] |
Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 17(4): 1206.
|
| [11] |
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis[J]. Cell, 1990, 61(5): 759-767.
|
| [12] |
Jensen CE, Villanueva JY, Loaiza-Bonilla A. Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma[J]. J Gastrointest Oncol, 2018, 9(5): 778-784.
|
| [13] |
Gao XH, Yu GY, Hong YG, et al. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients[J]. Int J Clin Oncol, 2019, 24(2): 141-152.
|
| [14] |
Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus Cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer[J]. J Cancer, 2018, 9(22): 4092-4098.
|
| [15] |
Juo YY, Johnston FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: A systematic review and meta-analysis[J]. Ann Oncol, 2014, 25(12): 2314-2327.
|
| [16] |
Gao XH, Yu GY, Gong HF, et al. Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer[J]. Sci Rep, 2017, 7(1): 7882.
|
| [17] |
Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location[J]. Ann Intern Med, 1990, 113(10): 779-788.
|
| [18] |
Modest DP, Schulz C, von Weikersthal LF, et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)[J]. Anticancer Drugs, 2014, 25(2): 212-218.
|
| [19] |
Loupakis F, Yang DY, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer[J]. J Natl Cancer Inst, 2015, 107(3): 1-9.
|
| [20] |
Ohhara Y, Fukuda N, Takeuchi S, et al. Role of targeted therapy in metastatic colorectal cancer[J]. World J Gastrointest Oncol, 2016, 8(9): 642-655.
|
| [21] |
Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO[J]. Ann Oncol, 2018, 29(7): 1528-1534.
|
| [22] |
Barana B, Ozupeka NM, Tetik NY, et al. Difference between left-sided and right-sided colorectal cancer: A focused review of literature[J]. Gastroenterol Res, 2018, 11(4): 264-273.
|
| [23] |
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8): 1386-1422.
|
| [24] |
Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wide-type metasticic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials[J]. JAMA Oncol, 2017, 3(2):194-201.
|
| [25] |
Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405(Alliance)[J]. J Clin Oncol, 2016, 34(1): 3504.
|
| [26] |
Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer（right-sided versus left-sided）as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17[J]. Eur J Cancer, 2015, 51(11): 1405-1414.
|
| [27] |
Wang F, Bai L, Liu TS, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab[J]. Chin J Cancer, 2015, 34(9): 384-393.
|
| [28] |
Qin S, Li J, Wang L, et al. Efficacy and tolerability of first-line Cetuximab plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial[J]. J Clin Oncol, 2018, 36(30): 3031-3039.
|
| [29] |
Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015, 16(6): 619-629.
|
| [30] |
Sehdev A, Cramer HM, Ibrahim AA, et al. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: A case report and review of literature[J]. Discov Med, 2016, 21(117): 341-347.
|
| [31] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [32] |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.
|
| [33] |
Benson AB, Venook AP, Cederquist L, et al. Colon Cancer, Version 1. 2017[J]. J Natl Compr Canc Netw, 2017, 15(3): 370-398.
|